| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 05/29/2002 | EP1207860A1 Controlled release pellet formulation |
| 05/29/2002 | EP1207858A1 Oral dosage forms |
| 05/29/2002 | EP1207811A1 Nitric oxide releasing medical devices |
| 05/29/2002 | EP1207807A2 Method for inducing hypothermia |
| 05/29/2002 | EP1207755A1 Methods of and compositions for inhibiting the proliferation of mammalian cells |
| 05/29/2002 | EP1061812A4 Food products having enhanced cocoa polyphenol content and processes for producing same |
| 05/29/2002 | EP0786457B1 Azole derivatives |
| 05/29/2002 | EP0752002B1 Inhibition of arterial smooth muscle cell proliferation |
| 05/29/2002 | DE10058663A1 Verwendung von Thienopyrimidinen Use of Thienopyrimidinen |
| 05/29/2002 | DE10058662A1 Verwendung von Pyrazolo[4,3-d]pyrimidinen Use of pyrazolo [4,3-d] pyrimidines |
| 05/29/2002 | CN1351713A Diagnosis and treatment of atherosclerosis and coronary heart disease |
| 05/29/2002 | CN1351614A Human antibodies that bind human IL-12 and methods for producing |
| 05/29/2002 | CN1351609A Low-molecular inhibitors of complement proteases |
| 05/29/2002 | CN1351604A Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease |
| 05/29/2002 | CN1351602A New pharmaceutically active compounds |
| 05/29/2002 | CN1351600A Process for preparing [S-(R*,S*)]-beta-[[[1-[1-OXO-3-(4-piperidinyl)propyl]-3-piperidinyl]amino]-3-pyridinepropanoic acid and derivatives |
| 05/29/2002 | CN1351599A Indole-type derivatives as inhibitors of P38 kinase |
| 05/29/2002 | CN1351594A Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents |
| 05/29/2002 | CN1351593A Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants agents |
| 05/29/2002 | CN1351592A Acyl derivatives which treat VL4-4 related disorders |
| 05/29/2002 | CN1351591A 抗炎吲哚衍生物 Indomethacin derivative |
| 05/29/2002 | CN1351497A Aminopyrimidines as sorbitol dehydrogenase inhibitors |
| 05/29/2002 | CN1351496A Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk |
| 05/29/2002 | CN1351492A synergistic effects of amlodipine and atorvastatin |
| 05/29/2002 | CN1351490A Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases |
| 05/29/2002 | CN1351174A Inhibiting material for inverting enzyme for angiotensin I |
| 05/29/2002 | CN1350859A Medicine for preventing and treating cardiovascular and cerebrovascular diseases |
| 05/29/2002 | CN1085667C Substituted tetracylic azepine derivatives having affinity for 5-HT2 receptors |
| 05/29/2002 | CN1085666C 6-aryl pyrido (2,3-d) pyrimidines and naphthyridines for inhibiting protein tyro sine kinase medicated cellular proliferation |
| 05/29/2002 | CN1085546C Medicine for curing coronary heart disease, arteriosclerosis and hypertension |
| 05/28/2002 | USRE37721 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| 05/28/2002 | US6395923 Antiischemic agents; cardiovascular disorders |
| 05/28/2002 | US6395897 Drugs for enzyme inhibitors anticoagulants and treatment of autoimmune disease |
| 05/28/2002 | US6395785 E-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol and pharmaceutical compositions thereof |
| 05/28/2002 | US6395784 Obesity, hypercholesterolemia, atherosclerosis, thyroid cancer, hypothyroidism, osteoporosis, depression, arrhythmia, and congestive heart failure treatment |
| 05/28/2002 | US6395781 Reducing vascular diameter |
| 05/28/2002 | US6395768 Preventing cytotoxic effect of amyloid protein; oxidation, stress resistance |
| 05/28/2002 | US6395767 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| 05/28/2002 | US6395764 Nosal decongestion, respiratory system disorders |
| 05/28/2002 | US6395754 Antiinflammatory agents, cardiovascular disorders, antipyretics |
| 05/28/2002 | US6395751 Synergistic mixture; anticholesterol agents |
| 05/28/2002 | US6395737 Malonic acid derivatives, processes for their preparation, for their use and pharmaceutical compositions containing them |
| 05/28/2002 | US6395736 Compositions and methods for the treatment of anorectal disorders |
| 05/28/2002 | US6395734 Anticancer agents |
| 05/28/2002 | US6395730 Potassium channel inhibitors |
| 05/28/2002 | US6395729 Use of pyridazino[4,5-b]indole-1-acetamide derivatives for preparing medicines for treating diseases related to the dysfunction of peripheral benzodiazepin receptors |
| 05/28/2002 | US6395722 Fatty acid derivatives of bile acids and bile acid derivatives |
| 05/28/2002 | US6395707 Methods of treatment utilizing variants of vascular endothelial cell growth factor |
| 05/28/2002 | US6395497 Suppression of leukocyte transferring in humans; administer immunoglobulins to humans, detect bound receptor, evaluate immune response |
| 05/28/2002 | US6395270 Activated protein C formulations |
| 05/28/2002 | US6395266 Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| 05/28/2002 | CA2221091C Estrogen agonist/antagonists treatment of atherosclerosis |
| 05/28/2002 | CA2203618C New metalloprotease inhibitors, their preparation process and the pharmaceutical compounds that contain them |
| 05/28/2002 | CA2181377C Tetracyclic derivatives, process of preparation and use |
| 05/28/2002 | CA2118997C Benzimidazole derivatives, their preparation and use |
| 05/28/2002 | CA2083274C The pharmacological use of certain cystine derivatives |
| 05/28/2002 | CA2038747C Selective adenosine receptor agents |
| 05/28/2002 | CA1341362C Human manganese superoxide dismutase cdna, its expression in bacteria and method of recovering enzymatically active human manganese superoxide dismutase |
| 05/23/2002 | WO2002040700A2 Corticotropin releasing factor receptor 2 deficient mice and uses thereof |
| 05/23/2002 | WO2002040692A2 Specific promoter of the human vascular endothelial cadherin-2 (hve-cad-2) gene and the therapeutic uses thereof |
| 05/23/2002 | WO2002040683A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/23/2002 | WO2002040671A2 Immunoglobulin superfamily proteins |
| 05/23/2002 | WO2002040666A2 Fat regulated genes, uses thereof, and compounds for modulating same |
| 05/23/2002 | WO2002040650A2 Methods for large scale production of recombinant dna-derived tpa or k2s molecules |
| 05/23/2002 | WO2002040629A2 Promoters exhibiting endothelial cell specificity and methods of using same |
| 05/23/2002 | WO2002040540A2 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 05/23/2002 | WO2002040517A2 M. tuberculosis chaperonin 60.1 and uses thereof |
| 05/23/2002 | WO2002040498A2 Reduction of antioxidant enzyme levels in tumor cells using antisense oligonucleotides |
| 05/23/2002 | WO2002040486A2 METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS |
| 05/23/2002 | WO2002040485A1 Preventive or therapeutic medicines for diabetes containing fused-heterocycle compounds or their salts |
| 05/23/2002 | WO2002040476A1 Pyridyl-substituted triazoles as tgf inhibitors |
| 05/23/2002 | WO2002040475A1 Bombesin receptor antagonists |
| 05/23/2002 | WO2002040469A1 Bombesin receptor antagonists |
| 05/23/2002 | WO2002040468A1 Compounds |
| 05/23/2002 | WO2002040467A1 Compounds |
| 05/23/2002 | WO2002040461A2 Aminoalkoxybiphenyl carboxamides as histamine-3 receptor ligands and their therapeutic applications |
| 05/23/2002 | WO2002040453A1 Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists |
| 05/23/2002 | WO2002040448A1 Pyridone derivatives as ap2 inhibitors |
| 05/23/2002 | WO2002040445A1 Glucagon antagonists/inverse agonists |
| 05/23/2002 | WO2002040052A1 Inhalation of nitric oxide |
| 05/23/2002 | WO2002040039A2 In vivo use of water absorbent polymers |
| 05/23/2002 | WO2002040038A2 M. tuberculosis chaperonin 10 and uses thereof |
| 05/23/2002 | WO2002040037A2 M. tuberculosis chaperonin 60.1 and uses thereof |
| 05/23/2002 | WO2002040032A2 Cytoprotective estrogen derivatives |
| 05/23/2002 | WO2002040030A1 Combination therapy for lowering and controlling intraocular pressure |
| 05/23/2002 | WO2002040026A1 A new use of a pyridazinone derivative |
| 05/23/2002 | WO2002040025A1 Anti-inflammatory agents |
| 05/23/2002 | WO2002040019A1 Benzimidazole derivatives |
| 05/23/2002 | WO2002040016A2 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 05/23/2002 | WO2002040013A1 Composition for stimulating the immune defence and iron metabolism, containing propionyl l-carnitine and lactoferrin |
| 05/23/2002 | WO2002040007A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 05/23/2002 | WO2002040005A2 Blockade of sodium channels by phenol derivatives |
| 05/23/2002 | WO2002040003A1 Method for producing an organic solvent-free lycopene concentrate, the resulting concentrate and composition comprising said concentrate |
| 05/23/2002 | WO2002039998A2 Methods and compositions for regulating memory consolidation |
| 05/23/2002 | WO2002039988A2 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists |
| 05/23/2002 | WO2002039984A2 Medicine based on anti-hyperglycaemic microcapsules with prolonged release |
| 05/23/2002 | WO2002039954A2 Novel compounds |
| 05/23/2002 | WO2002039953A2 Texaphyrin coordination compounds and uses thereof |
| 05/23/2002 | WO2002006213A3 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| 05/23/2002 | WO2002003970A3 Matrix controlled transdermal system for stabile derivatives of ace inhibitors |